BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

666 related articles for article (PubMed ID: 28487395)

  • 1. Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy.
    van den Brand JAJG; Ruggenenti P; Chianca A; Hofstra JM; Perna A; Ruggiero B; Wetzels JFM; Remuzzi G
    J Am Soc Nephrol; 2017 Sep; 28(9):2729-2737. PubMed ID: 28487395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination therapy with rituximab, low-dose cyclophosphamide, and prednisone for idiopathic membranous nephropathy: a case series.
    Cortazar FB; Leaf DE; Owens CT; Laliberte K; Pendergraft WF; Niles JL
    BMC Nephrol; 2017 Feb; 18(1):44. PubMed ID: 28143416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimized rituximab regimen versus recommended regimen for idiopathic membranous nephropathy: A single-center retrospective cohort study.
    Yan P; Fang X; Ke B
    Int Immunopharmacol; 2024 Mar; 130():111718. PubMed ID: 38377859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy.
    Ponticelli C; Altieri P; Scolari F; Passerini P; Roccatello D; Cesana B; Melis P; Valzorio B; Sasdelli M; Pasquali S; Pozzi C; Piccoli G; Lupo A; Segagni S; Antonucci F; Dugo M; Minari M; Scalia A; Pedrini L; Pisano G; Grassi C; Farina M; Bellazzi R
    J Am Soc Nephrol; 1998 Mar; 9(3):444-50. PubMed ID: 9513907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of rituximab in the treatment of membranous nephropathy: A systematic review and meta-analysis.
    Lu W; Gong S; Li J; Luo H; Wang Y
    Medicine (Baltimore); 2020 Apr; 99(16):e19804. PubMed ID: 32311997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A novel approach to rapid induction of remission in primary membranous nephropathy].
    Dobronravov VA; Bystrova OB; Kochoyan ZS; Fomicheva EN
    Ter Arkh; 2021 Jun; 93(6):706-712. PubMed ID: 36286838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunosuppression therapy for idiopathic membranous nephropathy: systematic review with network meta-analysis.
    Bose B; Chung EYM; Hong R; Strippoli GFM; Johnson DW; Yang WL; Badve SV; Palmer SC
    J Nephrol; 2022 May; 35(4):1159-1170. PubMed ID: 35199314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tacrolimus combined with corticosteroids versus Modified Ponticelli regimen in treatment of idiopathic membranous nephropathy: Randomized control trial.
    Ramachandran R; Hn HK; Kumar V; Nada R; Yadav AK; Goyal A; Kumar V; Rathi M; Jha V; Gupta KL; Sakhuja V; Kohli HS
    Nephrology (Carlton); 2016 Feb; 21(2):139-46. PubMed ID: 26205759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New insights into immune mechanisms underlying response to Rituximab in patients with membranous nephropathy: A prospective study and a review of the literature.
    Roccatello D; Sciascia S; Di Simone D; Solfietti L; Naretto C; Fenoglio R; Baldovino S; Menegatti E
    Autoimmun Rev; 2016 Jun; 15(6):529-38. PubMed ID: 26876383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of Rituximab, Low-Dose Cyclophosphamide, and Prednisone for Primary Membranous Nephropathy: A Case Series With Extended Follow Up.
    Zonozi R; Laliberte K; Huizenga NR; Rosenthal JK; Jeyabalan A; Collins AB; Cortazar FB; Niles JL
    Am J Kidney Dis; 2021 Dec; 78(6):793-803. PubMed ID: 34174365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy.
    Fernández-Juárez G; Rojas-Rivera J; Logt AV; Justino J; Sevillano A; Caravaca-Fontán F; Ávila A; Rabasco C; Cabello V; Varela A; Díez M; Martín-Reyes G; Diezhandino MG; Quintana LF; Agraz I; Gómez-Martino JR; Cao M; Rodríguez-Moreno A; Rivas B; Galeano C; Bonet J; Romera A; Shabaka A; Plaisier E; Espinosa M; Egido J; Segarra A; Lambeau G; Ronco P; Wetzels J; Praga M;
    Kidney Int; 2021 Apr; 99(4):986-998. PubMed ID: 33166580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous pulse cyclophosphamide and steroids induce immunological and clinical remission in New-incident and relapsing primary membranous nephropathy.
    Kanigicherla DAK; Hamilton P; Czapla K; Brenchley PE
    Nephrology (Carlton); 2018 Jan; 23(1):60-68. PubMed ID: 27778424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy.
    Jha V; Ganguli A; Saha TK; Kohli HS; Sud K; Gupta KL; Joshi K; Sakhuja V
    J Am Soc Nephrol; 2007 Jun; 18(6):1899-904. PubMed ID: 17494881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab versus steroids and cyclophosphamide for the treatment of primary membranous nephropathy: protocol of a pilot randomised controlled trial.
    Scolari F; Dallera N; Gesualdo L; Santoro D; Pani A; Santostefano M; Feriozzi S; Mani LY; Boscutti G; Messa P; Magistroni R; Quaglia M; Ponticelli C; Ravani P
    BMJ Open; 2019 Dec; 9(12):e029232. PubMed ID: 31806605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and safety of cyclophosphamide or tacrolimus therapy for idiopathic membranous nephropathy.
    Zou H; Jiang F; Xu G
    Ren Fail; 2019 Nov; 41(1):673-681. PubMed ID: 31354007
    [No Abstract]   [Full Text] [Related]  

  • 16. Rituximab for the treatment of idiopathic membranous nephropathy with nephrotic syndrome: a systematic review and meta-analysis.
    You L; Ye P; Xiao G; Liang J; Kong Y
    Turk J Med Sci; 2021 Dec; 51(6):2870-2880. PubMed ID: 34391323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of rituximab for primary membranous nephropathy with different clinical presentations: a retrospective study.
    Zhang S; Huang J; Dong J; Li Z; Sun M; Sun Y; Chen B
    Front Immunol; 2023; 14():1156470. PubMed ID: 37187749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapy of Rituximab in Idiopathic Membranous Nephropathy with Nephrotic Syndrome: A Systematic Review and Meta-analysis.
    Zou PM; Li H; Cai JF; Chen ZJ; Li C; Li XW
    Chin Med Sci J; 2018 Mar; 33(1):9-19. PubMed ID: 29620510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose rituximab is poorly effective in patients with primary membranous nephropathy.
    Moroni G; Depetri F; Del Vecchio L; Gallelli B; Raffiotta F; Giglio E; Brunini F; D'Amico M; Longhi S; Radice A; Messa P; Sinico RA
    Nephrol Dial Transplant; 2017 Oct; 32(10):1691-1696. PubMed ID: 27387472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of rituximab therapy for membranous nephropathy: a meta-analysis.
    Zhang J; Bian L; Ma FZ; Jia Y; Lin P
    Eur Rev Med Pharmacol Sci; 2018 Nov; 22(22):8021-8029. PubMed ID: 30536351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.